ArticleCureus2026
Prophylactic Aspirin Use Following Shoulder Surgery: A Retrospective Cohort Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background There is no clear consensus regarding the role of aspirin (acetylsalicylic acid, ASA) for venous thromboembolism (VTE) prophylaxis following shoulder arthroscopy or arthroplasty. Although rare, catastrophic complications have been reported surrounding the use of aspirin, or lack thereof, including deep vein thrombosis (DVT), hematoma, hospital readmission, and reoperation. Methodology We conducted a retrospective review of 1,272 patients who underwent shoulder arthroscopy or arthroplasty at a single institution between 2017 and 2023. Baseline demographic information, medical risk factors, chronic anticoagulation status, and the use of postoperative VTE/DVT prophylaxis were collected. Outcomes recorded within 90 days included VTE/DVT, symptomatic hematoma, readmission, and reoperation. Patients were stratified by procedure type and ASA use. Results Postoperatively, 70.8% of patients received ASA, which was not significantly associated with DVT (0.24% overall incidence, p = 0.9864), hematoma (p = 0.7254), reoperation (p = 0.2901), or readmission (p = 0.4326). Compared with arthroscopy, arthroplasty was associated with significantly higher rates of hematoma (2.46% vs. 0.19%, p < 0.0001), reoperation (4.43% vs. 1.03%, p = 0.0004), and readmission (5.91% vs. 0.37%, p < 0.0001). Chronic anticoagulation independently increased the risk of readmission (p = 0.0014) and reoperation (p = 0.0176), while advanced age was associated with higher rates of hematoma (p = 0.0027) and readmission (p = 0.0077). No significant associations were found between body mass index or diabetes and adverse outcomes. Conclusions The observed incidence of symptomatic VTE/DVT following shoulder arthroscopy and arthroplasty was low. Postoperative ASA use was not significantly associated with VTE/DVT or the evaluated postoperative complications. However, given the limited number of VTE/DVT events and nonrandomized treatment allocation, these findings do not establish equivalence between prophylaxis strategies or exclude a clinically meaningful benefit of ASA. Decisions regarding chemoprophylaxis should therefore be individualized according to patient and procedural risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.